

# Effect of Exercise Therapy on Lipid Parameters in Patients with End-Stage Renal Disease on Hemodialysis

Lorenzo Gordon, Donovan A McGrowder<sup>1</sup>, Yeiny T Pena<sup>2</sup>, Elsa Cabrera<sup>3</sup>, Marilyn Lawrence-Wright<sup>4</sup>

Kingston Public Hospital, North Street, Kingston, Jamaica, Departments of <sup>1</sup>Pathology and <sup>4</sup>Medicine, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica, <sup>2</sup>Department of Medicine, May Pen Hospital, Clarendon, Jamaica, <sup>3</sup>Department of Postgraduate Studies and Teaching, Hermanos Ameijeiras Hospital, Havana, Cuba

**Address for correspondence:** Dr. Lorenzo Gordon, E-mail: lorenzogordon@yahoo.com

## ABSTRACT

**Background:** Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease in chronic kidney disease patients.

**Aim:** This study investigated the impact of Hatha yoga exercise on lipid parameters in patients with end-stage renal disease (ESRD) on hemodialysis.

**Materials and Methods:** This prospective randomized study consisted of 33 ESRD patients in the *Hatha yoga* exercise group that was matched with 35 ESRD patients in the control group. Serum total cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol were determined at baseline (0 month) and after 4 months.

**Results:** Comparing values after 4 months versus baseline in the prehemodialysis Hatha yoga exercise group, there was found a significant decrease in total cholesterol from  $5.126 \pm 0.092$  mmol/l to  $4.891 \pm 0.072$  mmol/l (-4.58%;  $P = 0.0001$ ), triglycerides from  $2.699 \pm 0.078$  mmol/l to  $2.530 \pm 0.063$  mmol/l (-6.26%;  $P = 0.0001$ ), LDL-cholesterol from  $2.729 \pm 0.083$  mmol/l to  $2.420 \pm 0.066$  mmol/l (-11.32%;  $P = 0.0001$ ), and total cholesterol/HDL-cholesterol ratio from  $5.593 \pm 0.119$  mmol/l to  $4.907 \pm 0.116$  mmol/l (-12.26%;  $P = 0.047$ ). For patients in the Hatha yoga exercise group, 51.5% had normal total cholesterol at 0 month while 70.0% had normal total cholesterol ( $P < 0.05$ ) after 4 four months and 54.5% of patients had normal LDL-cholesterol at 0 month while 84.9% had normal LDL-cholesterol after 4 months ( $P < 0.05$ ).

**Conclusion:** These findings suggest that *Hatha yoga* exercise has preventive and beneficial effects and may be a safe therapeutic modality in ESRD patients.

**Keywords:** Cardiovascular, end-stage renal disease, hatha yoga exercise, total cholesterol

## INTRODUCTION

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD),<sup>[1,2]</sup> and is the leading cause of death in hemodialysis patients accounting

for almost 50 percent of deaths.<sup>[3]</sup> The number of patients with CKD is increasing due to premature CVD that manifests itself as a coronary heart disease (CHD).<sup>[4]</sup> Premature atherosclerotic CHD is driven by multiple risk factors, including dyslipidemia and oxidative stress, and there is evidence that end-stage renal disease (ESRD) patients on hemodialysis have atherogenic lipid abnormalities.<sup>[5]</sup>

The incidence of CVD is high in patients on hemodialysis and approximately two-thirds of all patients with ESRD suffer from dyslipidemia.<sup>[6]</sup> Dyslipidemia has been established as a well-known traditional risk factor for CVD in CKD patients on

Access this article online	
<b>Quick Response Code:</b> 	<b>Website:</b> <a href="http://www.jlponline.org">www.jlponline.org</a>
	<b>DOI:</b> 10.4103/0974-2727.98665

maintenance hemodialysis and contributes to the high cardiovascular morbidity and mortality in these patients.<sup>[17]</sup> Further, dyslipidemia is highly prevalent in patients on maintenance hemodialysis, with predominance of the atherogenic triad, i.e., hypertriglyceridemia, elevated very low-density lipoprotein (VLDL) and reduced high-density lipoprotein (HDL).<sup>[18]</sup> Hemodialysis patients also display elevated concentration of lipoprotein-a (LP-a), and total and low-density lipoprotein (LDL)-cholesterol levels usually remain within normal limits.<sup>[19]</sup> The kidney dialysis outcome quality initiative guidelines state that patients on maintenance hemodialysis with fasting triglycerides >5.65 mmol/l, LDL-cholesterol >2.59 mmol/l, and non-HDL-cholesterol >3.36 mmol/l, should be considered for treatment to reduce the cardiovascular complications in these patients.<sup>[10]</sup>

Patients with CKD are inactive and are characterized by severe functional limitations.<sup>[11,12]</sup> Although renal replacement treatment options, such as hemodialysis or peritoneal dialysis, reduce morbidity and mortality, ESRD patients still experience significantly low physical fitness and poor quality of life.<sup>[13,14]</sup> Their cardio-respiratory capacity is reported to be dramatically low.<sup>[15]</sup> The maximum oxygen consumption ( $VO_2$  max) in ESRD patients on hemodialysis is reported to be from 15.0 to 21.0 ml/kg/min, values that are half of those reported for healthy sedentary subjects, which range from 35.0 to 40.0 ml/kg/min.<sup>[16,17]</sup> Aerobic exercise interventions have been shown to increase  $VO_2$  max in selected patients.<sup>[18]</sup> Aerobic exercise training in patients with advanced CKD also reduced VLDL and triglyceride levels, and increase HDL-cholesterol levels.<sup>[19]</sup> It also improved arterial stiffness, an effect that had reversed by 1 month after training had ceased.<sup>[20]</sup>

*Hatha yoga* is becoming increasingly popular in western culture particularly as a tool for stress reduction and improving physical fitness. In eastern cultures, *yoga* has traditionally been a part of life, and practitioners of *yoga* are thought to be able to achieve high states of relaxation and self-regulation of stress. *Hatha yoga* uses a combination of *asanas* (postures), *pranayamas* (breathing), and *dhyana* (meditation). Although the exact mechanism is unknown, evidence suggests that the combination of these behaviors are most beneficial when utilized together.<sup>[21]</sup> *Hatha yoga* is one form of physical activity that, based upon previous research, may show promise for improving the health of caregivers.<sup>[22,23]</sup> Studies carried out on medium or long-term effect of *yoga* exercise on lipid parameters in ESRD patients are sparse and there is only one reported study in the literature that examined the effect of a modified

*yoga*-based exercise program on lipid parameters in hemodialysis patients.<sup>[24]</sup> This study investigated the impact of *Hatha yoga* exercise on lipid parameters in patients with ESRD on hemodialysis.

## MATERIALS AND METHODS

### Selection of subjects

The study was conducted between January 2009 and April 2009. There were two groups in the study. All the participants were recruited from the hemodialysis unit at the university hospital of the West Indies. The *yoga* group consisted on patients, who participated in 30 minutes of guided *Hatha Yoga* exercise and additional thirty minutes of instructed and unsupervised home training. The participants in the control group continued their regular lifestyle practice without direct intervention from the personnel of this investigation. The patients in the study were between 20 and 70 years of age, had no associated serious illness or harmful dependence on toxic habits and had signed consent form. The study was conducted in accordance with the Declaration of Helsinki.

Using the sample power statistical software (SPSS), set at type 1 error ( $\alpha$ ) = 0.05 and power of 90%, the minimum number of participants needed to pick up mean differences from normal was calculated to be five persons per group of interest. The groups of interest include analysis broken down by four age categories, two gender categories, four body mass index categories, and two overall grouping of cases versus controls. Hence a minimum of 66 participants (33 cases in the *Yoga* group and 33 control patients without a guided training program) were needed for this study. Cases and control patients were selected using a random sample from the sample frame of list of patients who attended that hemodialysis unit.

After obtaining informed consent, participants were asked to donate 5 ml of blood sample for lipid parameters measurements. Serum samples were processed and refrigerated within 3 hours of blood draw. The serum samples that were not assayed within 24 hours after collection, were stored at 2-8°C. Specimen held for longer times were stored at -70°C.

### Biochemical analysis

Biochemical assays of lipid profile parameters in the serum samples were performed with a multichannel auto analyzer (c8000, Abbott Diagnostics, Abbott Park, USA). Parameters that were determined include total cholesterol

(TC), triglyceride, HDL-cholesterol, and LDL-cholesterol. Total cholesterol was determined by an enzymatic method. The cholesterol esters are hydrolyzed to free cholesterol by cholesterol esterase. The free cholesterol is then oxidized by cholesterol oxidase to cholesten-3-one with the simultaneous production of hydrogen peroxide. The hydrogen peroxide produced couples with 4-aminoantipyrine and phenol, in the presence of peroxidase, to yield a chromogen with maximum absorbance at 505 nm.<sup>[25]</sup> HDL-cholesterol was measured by an enzymatic method on the supernatant obtained after selective precipitation of apolipoprotein B-containing lipoproteins with phosphotungstic acid in the presence of magnesium ions and centrifugation.<sup>[26]</sup> Triglyceride by an analytical methodology based on the sequence of reaction described by Fossati and colleagues.<sup>[27]</sup> In this direct colorimetric procedure, serum triglycerides are hydrolyzed by lipase, and the released glycerol is assayed in a reaction catalyzed by glycerol kinase and L-alpha-glycerol-phosphate oxidase in a system that generates hydrogen peroxide. The hydrogen peroxide is monitored in the presence of horseradish peroxidase with 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone as the chromogenic system. The absorbance of this chromogen system is measured at 510 nm.<sup>[27]</sup> The methods adopted by the automated instrument for the determination of the above parameters are according to the manufacturer's instruction, Abbott Laboratories (Abbott Diagnostics, Illinois, USA). Serum LDL-cholesterol was calculated according to computational procedures of Friedewald *et al.*:<sup>[28]</sup>

[LDL-cholesterol = total cholesterol - HDL-cholesterol - triglyceride/2.2 (mmol/l)].

Normal values of different parameters in lipid profile were considered as per NCEP ATP III [1] criteria guideline.<sup>[29]</sup> Total cholesterol of <5.18 mmol/l considered as normal, 5.18 – 6.19 mmol/l was considered as borderline high, whereas those  $\geq 6.20$  mmol/l were considered as high. Triglycerides values below 1.70 mmol/l were considered as normal; those 1.70-2.25 mmol/l were considered as border-line high, whereas values 2.26-5.64 mmol/l was considered as high and  $\geq 5.65$  mmol/l considered very high. Low-density lipoprotein values < 2.59 mmol/l were considered normal, between 2.59 – 3.34 mmol/l near optimal, 3.35 – 4.12 mmol/l were considered border-line high, 4.13 – 4.90 mmol/l was considered high, whereas values > 4.90 mmol/l were considered very high. High-density lipoprotein values below 1.04 mmol/l were considered as low,  $\geq 1.54$  mmol/l were considered as high, and values 1.04 – 1.53 mmol/l were considered as medium.<sup>[29]</sup>

## Statistical analysis

Values for the continuous variables were expressed as mean  $\pm$  SD. Comparisons of patients with ESRD in both groups were performed using unpaired students t-tests for independent samples, a level of  $P < 0.05$  considered as statistically significant. Independent observations were assumed using the Fisher exact test and 0.05 was taken to be the cutoff for acceptability of significance levels. The study parameters showed non-Gaussian distribution and statistical significance was assessed by the Mann-Whitney U test.<sup>[30]</sup> Statistics were computed using SPSS 11.5 (SPSS Inc., Chicago, Illinois, United States).

## RESULTS

The mean age of the patients in the *Hatha Yoga* exercise group was  $38.95 \pm 2.84$  years while that of the control group was  $44.59 \pm 2.57$  years. The mean BMI of the patients in the control group was  $25.74 \pm 0.50$  kg/m<sup>2</sup> while that of the *Hatha Yoga* exercise group was  $25.550 \pm 2.21$  kg/m<sup>2</sup>. The patients in the control group were in hemodialysis for  $4.45 \pm 0.65$  years while those in the *Hatha Yoga* exercise group were on hemodialysis for  $4.86 \pm 0.49$  years.

There was a significant reduction in serum total cholesterol, triglycerides, LDL-cholesterol, and total cholesterol/HDL-cholesterol ratio, and a significant increase in HDL-cholesterol after 4 months for patients in the Hatha yoga exercise group. In the prehemodialysis *Hatha Yoga* exercise group there was a significant decrease in total cholesterol from  $5.126 \pm 0.092$  mmol/l to  $4.891 \pm 0.072$  mmol/l (4.58% reduction;  $P = 0.0001$ ), triglycerides from  $2.699 \pm 0.078$  mmol/l to  $2.530 \pm 0.063$  mmol/l (6.26% reduction;  $P = 0.0001$ ), LDL-cholesterol from  $2.729 \pm 0.083$  mmol/l to  $2.420 \pm 0.066$  mmol/l (11.32% reduction  $P = 0.0001$ ), and total cholesterol/HDL-cholesterol ratio from  $5.593 \pm 0.119$  mmol/l to  $4.907 \pm 0.116$  mmol/l (12.26% reduction;  $P = 0.047$ ). Furthermore, there was no significant increase in HDL-cholesterol from  $0.931 \pm 0.022$  mmol/l to  $1.017 \pm 0.016$  mmol/l [8.46% elevation;  $P = 0.250$ ; Table 1].

There was a significant reduction in serum total cholesterol and HDL-cholesterol, and a significant increase in triglycerides and total cholesterol/HDL-cholesterol ratio after 4 months in the control group. In patients in the prehemodialysis control group was a significant reduction in serum total cholesterol from  $4.7663 \pm 0.050$  mmol/l to  $4.7657 \pm 0.054$  mmol/l ( $P = 0.0001$ ) and HDL-cholesterol from  $0.898 \pm 0.015$  mmol/l to  $0.872 \pm 0.013$  mmol/l

(2.90% reduction;  $P = 0.0001$ ). Furthermore, there was a significant increase in triglycerides from  $3.243 \pm 0.186$  mmol/l to  $3.450 \pm 0.180$  mmol/l (6.0% elevation;  $P = 0.0001$ ) and total cholesterol/HDL-cholesterol ratio from  $5.348 \pm 0.086$  to  $5.505 \pm 0.099$  [2.9% elevation;  $P = 0.0001$ ; Table 2].

There was significant correlation between the pre-dialysis lipid parameters of patients in the Hatha yoga exercise group at 0 month and after 4 months for total cholesterol ( $r = 0.655$ ), triglycerides ( $r = 0.826$ ), LDL-cholesterol ( $r = 0.572$ ), and total cholesterol/HDL-cholesterol ratio ( $r = 0.354$ ). Furthermore, there was significant correlation between the predialysis lipid parameters for the controls at 0 month and after 4 months for total cholesterol ( $r = 0.592$ ), triglycerides ( $r = 0.872$ ), HDL-cholesterol ( $r = 0.645$ ), and total cholesterol/HDL-cholesterol ratio ( $r = 0.584$ ).

In examining total cholesterol concentrations of patients in the prehemodialysis Hatha yoga exercise group, 51.5% had normal total cholesterol at 0 month, while at the end of therapy after 4 months 70.0% had normal total cholesterol ( $P < 0.05$ ). The results also showed that while 63.6% of the patients in the prehemodialysis *Hatha Yoga* exercise group had low HDL-cholesterol after 4 months, 81.8% had low HDL-cholesterol at 0 month ( $P < 0.05$ ). Furthermore, while 84.9% of patients in the prehemodialysis *Hatha Yoga* exercise group had normal LDL-cholesterol after 4 months, 54.5% had normal LDL-cholesterol at 0 month [ $P < 0.05$ ; Table 3]. In examining total cholesterol concentrations in the control group, 85.7% and 77.1% of the patients had normal total cholesterol concentrations at 0 month and 4 months respectively. There were no significant differences

**Table 1: Lipid parameters of prehemodialysis patients in the Hatha yoga exercise group**

Lipid parameters	Pre-HD 0 month Mean $\pm$ S.E.	Pre-HD 4 months Mean $\pm$ S.E.	P value
Total cholesterol (mmol/l)	5.126 $\pm$ 0.092	4.891 $\pm$ 0.072	0.0001*
Triglycerides (mmol/l)	2.699 $\pm$ 0.078	2.530 $\pm$ 0.063	0.0001*
HDL-cholesterol (mmol/l)	0.931 $\pm$ 0.022	1.017 $\pm$ 0.016	0.250
LDL-cholesterol (mmol/l)	2.729 $\pm$ 0.083	2.420 $\pm$ 0.066	0.0001*
TC/HDL-cholesterol ratio	5.593 $\pm$ 0.119	4.907 $\pm$ 0.116	0.047*

Total cholesterol (mmol/l). \*Statistical significance with  $P < 0.05$ .

**Table 2: Lipid parameters of prehemodialysis patients in the control group**

Lipid parameters	Pre-HD 0 month Mean $\pm$ S.E.	Pre-HD 4 months Mean $\pm$ S.E.	P value
Total cholesterol (mmol/l)	4.7663 $\pm$ 0.050	4.7657 $\pm$ 0.054	0.0001*
Triglycerides (mmol/l)	3.243 $\pm$ 0.186	3.450 $\pm$ 0.180	0.0001*
HDL-cholesterol (mmol/l)	0.898 $\pm$ 0.015	0.872 $\pm$ 0.013	0.0001*
LDL-cholesterol (mmol/l)	2.653 $\pm$ 0.086	2.611 $\pm$ 0.072	0.179
TC/HDL-cholesterol ratio	5.348 $\pm$ 0.086	5.505 $\pm$ 0.099	0.0001*

Total cholesterol (mmol/l). \*Statistical significance with  $P < 0.05$ .

in the normal triglycerides and LDL-cholesterol at 0 month compared with after 4 months in control patients [Table 4].

## DISCUSSION

Patients with chronic renal insufficiency and those on chronic hemodialysis treatment are at elevated atherogenic

**Table 3: Classification of lipid parameters of patients in the Hatha yoga exercise group (0 month and 4 months) according to NCEP ATP III**

Lipid parameters	Number (%)	
	0 month	4 months
Total cholesterol		
Normal $<5.18$ mmol/l	17 (51.5)	23 (70.0)
Borderline high 5.18–6.19 mmol/l	14 (42.4)	10 (30.0)
High $\geq 6.22$ mmol/l	2 (6.1)	0 (0.0)
Triglyceride		
Normal $<1.70$ mmol/l	1 (3.0)	1 (3.0)
Borderline high 1.70–2.25 mmol/l	4 (12.1)	5 (15.2)
High 2.26–5.64 mmol/l	28 (84.9)	27 (81.8)
Very high $\geq 5.65$ mmol/l	0 (0.0)	0 (0.0)
HDL-cholesterol		
Low $<1.04$ mmol/l	27 (81.8)	21 (63.6)
Medium 1.04–1.53 mmol/l	6 (18.2)	12 (36.4)
High $\geq 1.54$ mmol/l	0 (0.0)	0 (0.0)
LDL-cholesterol		
Normal $<2.59$ mmol/l	18 (54.5)	28 (84.9)
Near optimal/above optimal 2.59–3.34 mmol/l	12 (36.4)	4 (12.1)
Borderline high 3.35–4.12 mmol/l	3 (9.1)	1 (3.0)
High 4.13–4.90 mmol/l	0 (0.0)	0 (0.0)
Very high $\geq 4.90$ mmol/l	0 (0.0)	0 (0.0)

**Table 4: Classification of lipid parameters of patients in the control group (0 month and 4 months) according to NCEP ATP III**

Lipid parameters	Number (%)	
	0 month	4 months
Total cholesterol		
Normal $<5.18$ mmol/l	30 (85.7)	27 (77.1)
Borderline high 5.18–6.19 mmol/l	5 (14.3)	8 (22.9)
High $\geq 6.22$ mmol/l	0 (0.0)	0 (0.0)
Triglyceride		
Normal $<1.70$ mmol/l	1 (2.9)	1 (2.9)
Borderline high 1.70–2.25 mmol/l	4 (11.4)	2 (5.7)
High 2.26–5.64 mmol/l	30 (85.7)	32 (91.4)
Very high $\geq 5.65$ mmol/l	0 (0.0)	0 (0.0)
HDL-cholesterol		
Low $<1.04$ mmol/l	32 (91.4)	34 (97.1)
Medium 1.04–1.53 mmol/l	3 (8.6)	1 (2.9)
High $\geq 1.54$ mmol/l	0 (0.0)	0 (0.0)
LDL-cholesterol		
Normal $<2.59$ mmol/l	19 (54.3)	20 (57.1)
Near optimal/above optimal 2.59–3.34 mmol/l	11 (31.4)	9 (25.7)
Borderline high 3.35–4.12 mmol/l	5 (14.3)	6 (17.2)
High 4.13–4.90 mmol/l	0 (0.0)	0 (0.0)
Very high $>4.90$ mmol/l	0 (0.0)	0 (0.0)

risk, and dyslipidemia appears to be one of the major risk factors. Our study indicates an abnormal lipoprotein profile in ESRD patients on hemodialysis. The majority of the ESRD patients in both the *Hatha Yoga* exercise and control groups had borderline high or high triglycerides, and low HDL-cholesterol at baseline. Approximately one-tenth of the patients in both groups had high LDL-cholesterol concentrations while approximately one-half of the patients in the *Hatha Yoga* exercise group had borderline high or high total cholesterol. The ESRD patients engaged in *Hatha Yoga* exercise demonstrated significantly lower serum total cholesterol, triglycerides, LDL-cholesterol, and total cholesterol/LDL-cholesterol ratio after 4 months compared with baseline values. The risk factor for coronary artery disease (total cholesterol/HDL-cholesterol ratio) is usually elevated in renal failure patients, especially in those with hypertriglyceridemia.<sup>[31]</sup> Conversely, the ESRD patients in the control group had significantly higher triglycerides and total cholesterol/HDL-cholesterol ratio, but lower HDL-cholesterol concentrations after 4 months compared with baseline values. In the only study evaluating the effects of a 12-week yoga-based exercise program on biochemical markers in a randomized controlled trial of hemodialysis patients there was significant improvements in total cholesterol and LDL-cholesterol compared with that in the control group but not so in other lipid profile variables such as HDL-cholesterol and triglyceride concentrations. The authors concluded that the simplified yoga-based rehabilitation program is a complementary, safe, and effective clinical treatment modality in patients with ESRD.<sup>[32]</sup>

The results of this study are similar to that of Bijlani *et al*, where yoga significantly decreased serum total cholesterol, LDL-cholesterol, VLDL, triglycerides and total cholesterol/HDL-cholesterol ratio in individuals attending a lifestyle education-based program for 9 days.<sup>[32]</sup> Furthermore, there are studies that have investigated the use of yoga exercise as a therapeutic intervention in cardiovascular diseases. In a study by Khare and Rai investigating the lipid profile in postmyocardial infarction subjects following yogi life style intervention, there was significant reduction in total cholesterol and LDL-cholesterol, whereas an increase in HDL-cholesterol was also noted.<sup>[33]</sup> Mahajan *et al* reported that yoga intervention caused a decrease in all lipid parameters except HDL-cholesterol in angina patients and normal subjects with risk factors of coronary artery disease.<sup>[34]</sup> Yogendra *et al*, reported the beneficial effects of yoga lifestyle on reversibility of ischemic heart disease as at the end of 1 year of yoga training, statistical significant reductions in serum total cholesterol, serum LDL-cholesterol, and regression of

disease. The authors also suggest that yoga-based lifestyle modifications help in regression of coronary lesions and in improving myocardial perfusion which translated into clinical benefits and symptomatic improvement.<sup>[35]</sup>

Chronic renal failure is often associated with dyslipidemia. Lipid profile abnormalities have been identified as an independent risk factor for atherosclerosis.<sup>[36,37]</sup> ESRD patients typically have either normal or increased LDL-cholesterol, increased VLDL and intermediate-density lipoprotein (IDL), leading to elevated triglyceride levels, and decreased levels of HDL-cholesterol. There are also qualitative changes in dyslipidemia with a shift from an atherogenic LDL particle size toward a small, dense apo-B-rich LDL predominance.<sup>[6]</sup> It was reported by Algaran *et al* that 40-50% of patients with ESRD have high triglycerides, 10-45% have high LDL-cholesterol, and 20-30% have high total cholesterol.<sup>[38]</sup> In our study approximately 85% of the patients in both groups had high triglyceride concentrations greater than 2.26 mmol/l. Furthermore, 82-92% of the patients in both groups had low HDL-cholesterol. In the choices for healthy outcomes in caring for ESRD (CHOICE) study, 36% of hemodialysed patients had hypertriglyceridemia<sup>[39]</sup> where as Pennell and colleagues found the incidence to be 52%.<sup>[8]</sup> But the results of this study are not in agreement with the results of some researchers showing significantly decreased plasma triglyceride concentration in hemodialysis patients<sup>[40]</sup> or no change.<sup>[41]</sup> Furthermore, the atherogenic potential of dyslipidemia in kidney disease may depend more on the apolipoprotein rather than on lipid abnormalities, and may not always be recognized by measurement of plasma lipids alone,<sup>[42]</sup> as suggested by Attman and Alaupovic.<sup>[43]</sup>

In this study though there was not a significant increase in the mean value of HDL-cholesterol after 4 months, there was an increase in the number of patients with medium HDL-cholesterol, from 18.2% to 36.4%, with fewer people in the low category level. Some studies evaluating the long-term effect of yoga on lipid profile have demonstrated significant rise in values of HDL-cholesterol.<sup>[44,45]</sup> In the present study, there was a significant decrease in total cholesterol and triglyceride concentrations in ESRD patients on hemodialysis. Further, it was observed that some patients with borderline high total cholesterol and triglycerides values achieved normal values, whereas patients with high values achieved borderline high values. There were also some cases with high values that attained normal values. Hence, Hatha yoga intervention resulted in an overall improvement in different parameters of lipid profile and is therefore beneficial in the management of dyslipidemia in ESRD patients.

Many patients with renal failure show abnormalities of lipid metabolism. Hypertriglyceridemia and low levels of HDL-cholesterol are frequent abnormalities in uremic patients. The various disturbances of lipoprotein metabolism in uremia can be summarized as decreased catabolism of lipoproteins with an inappropriate synthesis of VLDL.<sup>[46]</sup> There is decreased lipoprotein catabolism, resulting in incompletely cleared intermediate particles and diminished formation of HDL.<sup>[47]</sup>

In conclusion, the findings of the study demonstrate the efficacy of *Hatha Yoga* exercise on lipid parameters in ESRD patients. These findings suggest that *Hatha Yoga* exercise has preventive and beneficial effects and may be a safe therapeutic modality in ESRD patients. Optimal management of dyslipidemia in ESRD patients with regimens such as *Hatha Yoga* exercise, particularly reduction of low-density lipoprotein cholesterol, should therefore lead to both cardiovascular and renal benefits.

## REFERENCES

- Junyent M, Martínez M, Borràs M, Coll B, Valdivielso JM, Vidal T, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. *BMC Nephrol* 2010;11:14.
- Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;32(5 Suppl 3):S112-9.
- Al Wakeel JS, Mitwalli AH, Al Mohaya S, Abu-Aisha H, Tarif N, Malik GH, et al. Morbidity and mortality in ESRD patients on dialysis. *Saudi J Kidney Dis Transpl* 2002;13:473-7.
- United States Renal Data System. USRDS (2000) Annual Data Report: Atlas of End-Stage Renal Disease in the United States (ed 12th Annual Report), Division of Kidney, Urologic and Hematological diseases. Bethesda, MD: National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health; 2000.
- Prichard SS. Impact of dyslipidemia in end-stage renal disease. *J Am Soc Nephrol* 2003;14(9 Suppl 4):S315-20.
- Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. *Semin Dial* 2006;19:32-40.
- Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. *Kidney Int Suppl* 2005;99:S87-93.
- Pennell P, Leclercq B, Delahunty MI, Walters BA. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney diseases. *Clin Nephrol* 2006;66:336-47.
- Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. *Circulation* 1992;86:475-82.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2 Suppl 1):S1-266.
- Barnea N, Drory Y, Iaina A, Lapidot G, Reisin E, Eliahou H, et al. Exercise tolerance in patients on chronic hemodialysis. *Isr J Med Sci* 1980;16:17-21.
- Moore G, Brinker K, Stray-Gundersen J, Mitchell J. Determinants of VO<sub>2</sub> peak in patients with end-stage renal disease: on and off dialysis. *Med Sci Sports Exerc* 1993;25:18-23.
- Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. *N Engl J Med* 1981;304:309-13.
- Evans RW, Manninen DL, Garrison LP. The quality of life of patients with end-stage renal disease. *N Engl J Med* 1985;312:553-9.
- Painter P, Messer-Rahak D, Hanson P, Zimmerman SW, Glass NR. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. *Nephron* 1986;42:47-51.
- Zabetakis PM, Gleim GW, Pasternack FL, Saraniti A, Nicholas JA, Michelis MF. Long-duration submaximal exercise conditioning in hemodialysis patients. *Clin Nephrol* 1982;18:17-22.
- Goldberg AP, Geltman EM, Hagberg JM, Gavin JR, Delmez JA, Carney RM, et al. Therapeutic benefits of exercise training for hemodialysis patients. *Kidney Int* 1983;24 (Suppl 16):S303-9.
- Johansen KL. Exercise and chronic kidney disease: Current recommendations. *Sports Med* 2005;35:485-99.
- Goldberg AP, Geltman EM, Gavin JR III. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. *Nephron* 1986;42:311-6.
- Mustata S, Chan C, Lai V, Miller JA. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. *J Am Soc Nephrol* 2004;15:2713-8.
- Kirkwood G, Ramps H, Tuffrey V, Richardson J, Pilkington K. Yoga for anxiety: a systematic review of the research evidence. *Br J Sports Med* 2005;39:884-91.
- Raub JA. Psychophysiological effects of Hatha yoga on musculoskeletal and cardiopulmonary function: a literature review. *J Altern Complement Med* 2002;8:797-812.
- Kolasinski SL, Garfinkel M, Tsai AG, Matz W, Van Dyke A, Schumacher HR. Iyengar yoga for treating symptoms of osteoarthritis of the knees: A pilot study. *J Altern Complement Med* 2005;11:689-93.
- Yurtkuran M, Alp A, Yurtkuran M, Dilek K. A modified yoga-based exercise program in hemodialysis patients: a randomized controlled study. *Complement Ther Med* 2007;15:164-71.
- Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. *Clin Chem* 1974;20:470-5.
- Burstein M, Scholnick HR, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. *J Lipid Res* 1970;11:583-95.
- Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin Chem* 1982;28:2077-80.
- Friedewald WJ, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *J Am Med Assoc* 2001;285:2486-97.
- Feinstein A. *Clinical epidemiology, the architecture of clinical research*. 1st ed. Philadelphia: WB Saunders Co; 1985.
- Chan MK. Lipid metabolism in renal failure. *Clin Biochem* 1990;23:61-65.
- Bijlani RL, Vempati RP, Yadav RK, Ray RB, Gupta V, Sharma R, et al. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. *J Altern Complement Med* 2005;11:267-74.
- Khare KC, Rai S. Study of lipid profile in post myocardial infarction subjects following yogic life style intervention. *The Indian Practitioner* 2002;55:369-73.
- Mahajan AS, Reddy KS, Sachdeva U. Lipid profile of coronary risk subjects following yogic lifestyle intervention. *Indian Heart J* 1999;51:37-40.
- Yogendra J, Yogendra HJ, Ambardekar S, et al. Beneficial effects of yoga lifestyle on reversibility of ischaemic heart disease: caring heart project of International Board of Yoga. *J Assoc Physicians India* 2004;52:283-9.
- Assman G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular munster study. *Am J Cardiol* 1992;70:733-7.
- Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. *J Cardiovasc Risk* 1996;3:213-9.
- Alsaran K, Sabry A, Shaheen N. Is non-fasting non-high-density lipoprotein cholesterol adequate for lipid management in Saudi hemodialysis patients? *J Nephrology and Renal Transplantation* 2009;2:1-17.

39. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, *et al.* Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *J Am Soc Nephrol* 2002;13:1918-27.
40. Ibels LS, Simons LA, King JD. Plasma post heparin lipolytic activity and triglyceride clearance in uremic hemodialysis patients and renal allograft recipients. *Lab Clin Med* 1976;87:648-58.
41. Sharma BK, Jindal SK, Rana DS. Absence of hyperlipidemia in patients of chronic renal failure in Chandigarh. *Indian J Med Res* 1980;72:461-64.
42. Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, *et al.* Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. *J Am Soc Nephrol* 2002;13:461-9.
43. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. *Nephron* 1991;57:401-10.
44. Verdich C, Toubro S, Buemann B, Holst JJ, Bülow J, Simonsen L, *et al.* Leptin levels are associated with fat oxidation and dietary-induced weight loss in obesity. *Obes Res* 2001;9:452-61.
45. Jequier E, Tappy L. Regulation of body weight in humans. *Physiol Rev* 1999;79:451-80.
46. Heuck CC, Ritz E. Hyperlipoproteinemia in renal insufficiency. *Nephron* 1980;25:1-7.
47. Querfeld U. Disturbances of lipid metabolism in children with chronic renal failure. *Pediatric Nephrology* 1993;7:749-57.

**How to cite this article:** Gordon L, McGrowder DA, Pena YT, Cabrera E, Lawrence-Wright M. Effect of exercise therapy on lipid parameters in patients with end-stage renal disease on hemodialysis. *J Lab Physicians* 2012;4:17-23.

**Source of Support:** There is no competing financial or other interest in relation to this research. **Conflict of Interest:** None declared.

### Author Help: Online submission of the manuscripts

Articles can be submitted online from <http://www.journalonweb.com>. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) **First Page File:**

Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) **Article File:**

The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1024 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) **Images:**

Submit good quality color images. Each image should be less than **4096 kb (4 MB)** in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) **Legends:**

Legends for the figures/images should be included at the end of the article file.